Skip to main content

PAPEL DE PROTEINAS DE FUSION MITOCONDRIAL Y DE LA AUTOFAGIA EN EL CONTROL DEL METABOLISMO Y LA INFLAMACION , E IMPACTO EN PATOLOGIA

PID2019-106209RB-I00

•
Funding agency name Agencia Estatal de Investigación
Funding agency acronym AEI
Program Programa Estatal de I+D+i Orientado a los Retos de la Sociedad
Call Proyectos de I+D+i (Generación de Conocimiento y Retos Investigación)
Call year 2019
State Plan 2017-2020 Plan Estatal de Investigación Científica y Técnica y de Innovación
Beneficiary centre FUNDACIO INSTITUT DE RECERCA BIOMEDICA (BARCELONA)

Resultados relacionados

Resultados totales (Incluyendo duplicados): 7
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publication Artículo de revisión (ReviewArticle)

Mechanisms of Modulation of Mitochondrial Architecture

  • Muñoz, Juan Pablo|||0000-0003-0912-4168
  • Basei, Fernanda Luisa|||0000-0001-6232-7170
  • Rojas, Maria Laura|||0000-0001-9849-7163
  • Galvis, David
  • Zorzano Olarte, Antonio|||0000-0002-1638-0306
Mitochondrial network architecture plays a critical role in cellular physiology. Indeed, alterations in the shape of mitochondria upon exposure to cellular stress can cause the dysfunction of these organelles. In this scenario, mitochondrial dynamics proteins and the phospholipid composition of the mitochondrial membrane are key for fine-tuning the modulation of mitochondrial architecture. In addition, several factors including post-translational modifications such as the phosphorylation, acetylation, SUMOylation, and o-GlcNAcylation of mitochondrial dynamics proteins contribute to shaping the plasticity of this architecture. In this regard, several studies have evidenced that, upon metabolic stress, mitochondrial dynamics proteins are post-translationally modified, leading to the alteration of mitochondrial architecture. Interestingly, several proteins that sustain the mitochondrial lipid composition also modulate mitochondrial morphology and organelle communication. In this context, pharmacological studies have revealed that the modulation of mitochondrial shape and function emerges as a potential therapeutic strategy for metabolic diseases. Here, we review the factors that modulate mitochondrial architecture.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

MAP kinase ERK5 modulates cancer cell sensitivity to extrinsic apoptosis induced by death-receptor agonists

  • Espinosa-Gil, Sergio|||0000-0002-2873-8475
  • Alari Pahissa, Elisenda|||0000-0001-7424-5383
  • Villafranca-Magdalena, Beatriz|||0000-0001-9921-919X
  • Viñas-Casas, Maria|||0000-0003-1438-7325
  • Gamez-Garcia, Andrés|||0000-0003-4927-3678
  • Colás Ortega, Eva|||0000-0003-0302-4828
  • López-Botet, Miguel|||0000-0003-4882-065X
  • Zorzano Olarte, Antonio|||0000-0002-1638-0306
  • Lizcano de Vega, José Miguel|||0000-0002-3154-5383
  • Ivanova, Saska
  • Denizli, Melek|||0000-0002-9325-2535
  • Faúndez Vidiella, Claudia
Death receptor ligand TRAIL is a promising cancer therapy due to its ability to selectively trigger extrinsic apoptosis in cancer cells. However, TRAIL-based therapies in humans have shown limitations, mainly due inherent or acquired resistance of tumor cells. To address this issue, current efforts are focussed on dissecting the intracellular signaling pathways involved in resistance to TRAIL, to identify strategies that sensitize cancer cells to TRAIL-induced cytotoxicity. In this work, we describe the oncogenic MEK5-ERK5 pathway as a critical regulator of cancer cell resistance to the apoptosis induced by death receptor ligands. Using 2D and 3D cell cultures and transcriptomic analyses, we show that ERK5 controls the proteostasis of TP53INP2, a protein necessary for full activation of caspase-8 in response to TNFα, FasL or TRAIL. Mechanistically, ERK5 phosphorylates and induces ubiquitylation and proteasomal degradation of TP53INP2, resulting in cancer cell resistance to TRAIL. Concordantly, ERK5 inhibition or genetic deletion, by stabilizing TP53INP2, sensitizes cancer cells to the apoptosis induced by recombinant TRAIL and TRAIL/FasL expressed by Natural Killer cells. The MEK5-ERK5 pathway regulates cancer cell proliferation and survival, and ERK5 inhibitors have shown anticancer activity in preclinical models of solid tumors. Using endometrial cancer patient-derived xenograft organoids, we propose ERK5 inhibition as an effective strategy to sensitize cancer cells to TRAIL-based therapies. {'@id': 'Par2', 'graphic': {'@position': 'anchor', '@xlink:href': '41419_2023_6229_Figa_HTML', '@id': 'd32e443'}}.
Repositorio Digital de la UPF
Publication Artículo científico (JournalArticle)

MAP kinase ERK5 modulates cancer cell sensitivity to extrinsic apoptosis induced by death-receptor agonists

  • Espinosa-Gil, Sergio
  • Ivanova, Saska
  • Alari-Pahissa, Elisenda
  • Denizli, Melek
  • Villafranca-Magdalena, Beatriz
  • Viñas-Casas, Maria
  • Bolinaga-Ayala, Idoia
  • Gámez-García, Andrés
  • Faundez-Vidiella, Claudia
  • Colas, Eva
  • López-Botet, M. (Miguel)
  • Zorzano, Antonio
  • Lizcano, José Miguel
Death receptor ligand TRAIL is a promising cancer therapy due to its ability to selectively trigger extrinsic apoptosis in cancer cells. However, TRAIL-based therapies in humans have shown limitations, mainly due inherent or acquired resistance of tumor cells. To address this issue, current efforts are focussed on dissecting the intracellular signaling pathways involved in resistance to TRAIL, to identify strategies that sensitize cancer cells to TRAIL-induced cytotoxicity. In this work, we describe the oncogenic MEK5-ERK5 pathway as a critical regulator of cancer cell resistance to the apoptosis induced by death receptor ligands. Using 2D and 3D cell cultures and transcriptomic analyses, we show that ERK5 controls the proteostasis of TP53INP2, a protein necessary for full activation of caspase-8 in response to TNFα, FasL or TRAIL. Mechanistically, ERK5 phosphorylates and induces ubiquitylation and proteasomal degradation of TP53INP2, resulting in cancer cell resistance to TRAIL. Concordantly, ERK5 inhibition or genetic deletion, by stabilizing TP53INP2, sensitizes cancer cells to the apoptosis induced by recombinant TRAIL and TRAIL/FasL expressed by Natural Killer cells. The MEK5-ERK5 pathway regulates cancer cell proliferation and survival, and ERK5 inhibitors have shown anticancer activity in preclinical models of solid tumors. Using endometrial cancer patient-derived xenograft organoids, we propose ERK5 inhibition as an effective strategy to sensitize cancer cells to TRAIL-based therapies., SE-G and AG-G: are recipients of a fellowship from FI-AGAUR (2020-FISDU-00575 and FI_B 00293, respectively). I.B.A. is recipient of a PIF fellowship from UAB. MV-C is recipient of a PFU fellowship (Ref. FPU21/01999). B.V.M. is recipient of a PFIS fellowship (ref. FI21/00271). JML acknowledges support from Spanish Ministry of Economy and Competitiveness (MINECO, SAF2015-64237-R), Spanish Ministry of Science and Innovation (PID2019-107561RB-I00 and PID2022-136391OB-I00), and co-funded by the European Regional Development Fund (ERDF, “A way to make Europe/Investing in your future”). E.C. was founded by Fundación Científica Asociación Española Contra el Cáncer (AECC, GCTRA1804MATI) and Generalitat de Catalunya (2021-SGR-01157). AZ acknowledges support by research grants from MINECO (PID2019-106209RB-I00), CIBERDEM (Instituto de Salud Carlos III), and from an ICREA “Academia” Award (Generalitat de Catalunya). ML-B acknowledges support by research grant PID2019-110609RB-C21 from MCIN/AEI/ 10.13039/501100011033.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Cardiac fibroblasts display endurance to ischemia, high ROS control and elevated respiration regulated by the JAK2/STAT pathway

  • Beà, Aida
  • García Valero, Juan
  • Irazoki, Andrea
  • Lana, Carlos
  • López-Lluch, Guillermo
  • Portero-Otín, Manuel
  • Pérez-Galán, Patricia
  • Inserte, Javier
  • Ruiz-Meana, Marisol
  • Zorzano, Antonio
  • Llovera, Marta
  • Sanchis, Daniel
Cardiovascular diseases are the leading cause of death globally and more than four out of five cases are due to ischemic events. Cardiac fibroblasts (CF) contribute to normal heart development and function, and produce the post-ischemic scar. Here, we characterize the biochemical and functional aspects related to CF endurance to ischemia-like conditions. Expression data mining showed that cultured human CF (HCF) express more BCL2 than pulmonary and dermal fibroblasts. In addition, gene set enrichment analysis showed overrepresentation of genes involved in the response to hypoxia and oxidative stress, respiration and Janus kinase (JAK)/Signal transducer and Activator of Transcription (STAT) signaling pathways in HCF. BCL2 sustained survival and proliferation of cultured rat CF, which also had higher respiration capacity and reactive oxygen species (ROS) production than pulmonary and dermal fibroblasts. This was associated with higher expression of the electron transport chain (ETC) and antioxidant enzymes. CF had high phosphorylation of JAK2 and its effectors STAT3 and STAT5, and their inhibition reduced viability and respiration, impaired ROS control and reduced the expression of BCL2, ETC complexes and antioxidant enzymes. Together, our results identify molecular and biochemical mechanisms conferring survival advantage to experimental ischemia in CF and show their control by the JAK2/STAT signaling pathway. The presented data point to potential targets for the regulation of cardiac fibrosis and also open the possibility of a general mechanism by which somatic cells required to acutely respond to ischemia are constitutively adapted to survive it., This research was funded by Ministerio de Ciencia e Innovación (MICINN), Gobierno de España, grant numbers SAF2013-44942-R and PID2019-104509RB-I00 to DS; Fundació La Marató TV3, grant number 20153810 to D.S; A.B. holds a contract from Fundació La Marató TV3 and IRBLleida/Diputació de Lleida; Generalitat de Catalunya, (AGAUR) grant number 2017SGR996 to DS; PP-G Laboratory support was obtained through research grants from MICINN (SAF2017/88275R) and CIBERONC (CB16/12/00334); JI and MR-M Laboratory support was obtained from Instituto de Salud Carlos III (ISCIII-FIS) grant PI19-01196; AZ Laboratory support was obtained through research grants from MICINN (PID2019-106209RB-I00), and the Generalitat de Catalunya, (AGAUR) grant number 2017SGR1015. AZ is a recipient of an ICREA ‘Academia’ Award (Generalitat de Catalunya). We gratefully acknowledge institutional funding from the MINECO through the Centres of Excellence Severo Ochoa Award, and from the CERCA Programme of the Generalitat de Catalunya.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

The NADPH oxidase NOX4 regulates redox and metabolic homeostasis preventing HCC progression

  • Peñuelas-Haro, Irene
  • Espinosa-Sotelo, Rut
  • Crosas-Molist, Eva
  • Herranz-Itúrbide, Macarena
  • Caballero-Díaz, Daniel
  • Alay, Ania
  • Solé, Xavier
  • Ramos, Emilio
  • Serrano, Teresa
  • Martínez-Chantar, María Luz
  • Knaus, Ulla G.
  • Cuezva, José M.
  • Zorzano, Antonio
  • Bertran, Esther
  • Fabregat, Isabel
Background and aims: The NADPH oxidase NOX4 plays a tumor-suppressor function in HCC. Silencing NOX4 confers higher proliferative and migratory capacity to HCC cells and increases their in vivo tumorigenic potential in xenografts in mice. NOX4 gene deletions are frequent in HCC, correlating with higher tumor grade and worse recurrence-free and overall survival rates. However, despite the accumulating evidence of a protective regulatory role in HCC, the cellular processes governed by NOX4 are not yet understood. Accordingly, the aim of this work was to better understand the molecular mechanisms regulated by NOX4 in HCC in order to explain its tumor-suppressor action. Approach and results: Experimental models: cell-based loss or gain of NOX4 function experiments, in vivo hepatocarcinogenesis induced by diethylnitrosamine in Nox4-deficient mice, and analyses in human HCC samples. Methods include cellular and molecular biology analyses, proteomics, transcriptomics, and metabolomics, as well as histological and immunohistochemical analyses in tissues. Results identified MYC as being negatively regulated by NOX4. MYC mediated mitochondrial dynamics and a transcriptional program leading to increased oxidative metabolism, enhanced use of both glucose and fatty acids, and an overall higher energetic capacity and ATP level. NOX4 deletion induced a redox imbalance that augmented nuclear factor erythroid 2-related factor 2 (Nrf2) activity and was responsible for MYC up-regulation. Conclusions: Loss of NOX4 in HCC tumor cells induces metabolic reprogramming in a Nrf2/MYC-dependent manner to promote HCC progressio, Supported by Agencia Estatal de Investigación, Ministerio de Ciencia e Innovación, Spain (co‐funded by European Regional Development Fund ERDF, a way to build Europe) (SAF2015‐64149‐R, RTI2018‐094079‐B‐100, PID2021‐122551OB‐I00, PID2019‐106209RB‐I00, PID2019‐108674RB‐100, and RED2018‐102576‐T); FPI fellowships (BES‐2016‐077564 and PRE2019‐089144); the Generalitat de Catalunya (2017SGR1015); Science Foundation Ireland (16/IA/4501); CIBER, National Biomedical Research Institute, which is funded by the Instituto de Salud Carlos III, Spain; CERCA Programme/Generalitat de Catalunya; and an ICREA “Academia” Award (Generalitat de Catalunya)
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

MAP kinase ERK5 modulates cancer cell sensitivity to extrinsic apoptosis induced by death-receptor agonists

  • Espinosa-Gil, Sergio
  • Ivanova, Saska
  • Alari-Pahissa, Elisenda
  • Denizli, Melek
  • Villafranca-Magdalena, Beatriz
  • Viñas-Casas, Maria
  • Bolinaga-Ayala, Idoia
  • Gámez-García, Andrés
  • Faundez-Vidiella, Claudia
  • Colas, Eva
  • López-Botet, M. (Miguel)
  • Zorzano, Antonio
  • Lizcano, José Miguel
Death receptor ligand TRAIL is a promising cancer therapy due to its ability to selectively trigger extrinsic apoptosis in cancer cells. However, TRAIL-based therapies in humans have shown limitations, mainly due inherent or acquired resistance of tumor cells. To address this issue, current efforts are focussed on dissecting the intracellular signaling pathways involved in resistance to TRAIL, to identify strategies that sensitize cancer cells to TRAIL-induced cytotoxicity. In this work, we describe the oncogenic MEK5-ERK5 pathway as a critical regulator of cancer cell resistance to the apoptosis induced by death receptor ligands. Using 2D and 3D cell cultures and transcriptomic analyses, we show that ERK5 controls the proteostasis of TP53INP2, a protein necessary for full activation of caspase-8 in response to TNFα, FasL or TRAIL. Mechanistically, ERK5 phosphorylates and induces ubiquitylation and proteasomal degradation of TP53INP2, resulting in cancer cell resistance to TRAIL. Concordantly, ERK5 inhibition or genetic deletion, by stabilizing TP53INP2, sensitizes cancer cells to the apoptosis induced by recombinant TRAIL and TRAIL/FasL expressed by Natural Killer cells. The MEK5-ERK5 pathway regulates cancer cell proliferation and survival, and ERK5 inhibitors have shown anticancer activity in preclinical models of solid tumors. Using endometrial cancer patient-derived xenograft organoids, we propose ERK5 inhibition as an effective strategy to sensitize cancer cells to TRAIL-based therapies., SE-G and AG-G: are recipients of a fellowship from FI-AGAUR (2020-FISDU-00575 and FI_B 00293, respectively). I.B.A. is recipient of a PIF fellowship from UAB. MV-C is recipient of a PFU fellowship (Ref. FPU21/01999). B.V.M. is recipient of a PFIS fellowship (ref. FI21/00271). JML acknowledges support from Spanish Ministry of Economy and Competitiveness (MINECO, SAF2015-64237-R), Spanish Ministry of Science and Innovation (PID2019-107561RB-I00 and PID2022-136391OB-I00), and co-funded by the European Regional Development Fund (ERDF, “A way to make Europe/Investing in your future”). E.C. was founded by Fundación Científica Asociación Española Contra el Cáncer (AECC, GCTRA1804MATI) and Generalitat de Catalunya (2021-SGR-01157). AZ acknowledges support by research grants from MINECO (PID2019-106209RB-I00), CIBERDEM (Instituto de Salud Carlos III), and from an ICREA “Academia” Award (Generalitat de Catalunya). ML-B acknowledges support by research grant PID2019-110609RB-C21 from MCIN/AEI/ 10.13039/501100011033.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

FTY720-P, a Biased S1PR Ligand, Increases Mitochondrial Function through STAT3 Activation in Cardiac Cells